News for Healthier Living

NK Cells Complexed with Bispecific Antibody Yield High Response Rates in Patients with Lymphoma

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center.

April 4, 2025


April 9 2025

April 8 2025

April 7 2025

April 5 2025

April 4 2025

April 3 2025

April 2 2025

April 1 2025

March 31 2025

March 30 2025

March 29 2025

March 28 2025

March 27 2025

March 26 2025